Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

Mangia, Alessandra; Bandiera, Franco; Montalto, Giuseppe; Mottola, Leonardo; Piazzolla, Valeria; Minerva, Nicola; Pellicelli, A.; Ricci, Giovanni; Cela, Marina; Carretta, Vito; Scotto, Gaetano; Bacca, D.; Annicchiarico, B.E.; Romano, Mario R.; Russello, Maurizio; Barbarini, Giorgio; Agostinacchio, Ernesto; Andriulli, Angelo

doi:10.1016/j.jhep.2010.04.042

Cited by 26 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with other reports, our data suggested that an RVR is highly predictive of a sustained virological response [4, 6, 7, 16, 18, 24, 27]. In the present cohort the rate of negative HCV RNA results at week 4 was significantly higher in patients with an SVR compared to those without (44.3% vs. 8.3%).…”

Section: Discussionsupporting

confidence: 92%

“…To define the predictive value of biochemical parameters we assessed the potential link between baseline ALT, GGT activity and response to antiviral treatment, and only GGT level was found to be correlated highly with SVR as an independent factor; these results are consistent with those reported by other investigators [12, 16, 27]. We did not confirm the correlation between pretreatment ALT level and sustained virological response observed by some investigators [6, 25, 27, 28].…”

Section: Discussionsupporting

confidence: 59%

See 1 more Smart Citation

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

Zarębska-Michaluk

Lebensztejn

Chrapek

et al. 2016

ceh

View full text Add to dashboard Cite

Aim of the studyTo assess predictors of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 3 treated with standard therapy.Material and methodsWe retrospectively investigated data of 116 consecutive treatment-naïve patients chronically infected with HCV genotype 3, treated with pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 24 weeks. HCV RNA at week 4 (rapid virological response – RVR) and week 12 (early virological response – EVR) were measured in 85 and 105 patients respectively. Liver biopsy data were available for 103 patients. The variables were compared between patients with an SVR and those without.ResultsOverall 70.7% of patients achieved an SVR. Pretreatment factors including younger age, mild liver fibrosis as well as normal values of gamma-glutamyl transferase (GGT) and platelet count were significantly associated with higher SVR rate in univariate analysis. In the multivariate analysis only baseline platelet count > 140 000/µl and normal GGT activity were correlated with higher SVR rate. At weeks 4 and 12 HCV RNA was undetectable in 34.1% and 84.8% of patients respectively. The SVR rate was significantly higher in patients with an RVR compared to those without (p = 0.002). Only 2 patients with a rapid and early virological response did not achieve an SVR; both had negative pretreatment prognostic factors.ConclusionsIn treatment-naïve patients with genotype 3 HCV infection, low baseline platelet count and elevated GGT activity were significantly associated with poor response to PegIFNα and RBV. Achieving a rapid and early virological response was associated with higher likelihood of an SVR.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 59%

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

Zarębska-Michaluk

Lebensztejn

Chrapek

et al. 2016

ceh

View full text Add to dashboard Cite

show abstract

“…Notably, this difference was not related to a decrease in the relapse rate (36-week: 20%, 24-week: 18%). Baseline viral load did not affect the rate of SVR in patients with an RVR, but unfortunately this was not reported for those without an RVR [20]. Although this well-conducted study sheds light into the role of RVR for tailoring the length of treatment in G3 patients, their non-inferiority design is only appropriate for RVR patients (12-vs 24-week comparison), but not for the non-RVR group (24-vs 36-week comparison), thereby, limiting the interpretation of these exciting results.…”

Section: Extended or Intensive Courses Of Therapy In Genotypes 2 Andmentioning

confidence: 84%

“…Treatment for G3 is less straightforward. Viral load seems to be more relevant in G3 than G2, as it affects both the rate of RVR [20] and increases the chance of relapse [21]. Patients who achieve RVR do well with a standard 24-week course of therapy and some data suggest that treatment can be shortened in such individuals.…”

Section: Genotypementioning

confidence: 99%

‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?

Duarte‐Rojo

Heathcote

Feld

2011

Journal of Hepatology

View full text Add to dashboard Cite

Genotypes 2 and 3 (G2/G3) of hepatitis C virus have been lumped together as 'easy to treat'. As a result, guidelines recommend 24 weeks of peginterferon/ribavirin for both. However, a closer look at trials shows that these genotypes are not the same, with G2 infection proving more responsive to peginterferon. The data supporting this conclusion are presented along with possible explanations for the differences observed. Ultimately, decisions must be made about therapy. Rapid virological response (RVR) may be the best parameter predicting successful antiviral therapy. For patients with G2 infection who achieve an RVR, shortened courses of therapy are effective. In contrast, for G3 patients without an RVR, there may be benefit to extending therapy to 48 weeks; however, this requires confirmation in prospective studies. Using RVR to guide therapy may level the playing field between these 'easy to treat' genotypes.

show abstract

“…Multiple randomized controlled trials [15][16][17][18][19][20], detailed in Table 1, have demonstrated moderate rates of efficacy to pegylated interferon (PEG)-based therapy. Overall, SVR rates range from 42 to 93 % across these studies.…”

Section: Treatmentmentioning

confidence: 99%

Hepatitis C genotype 3 disease

et al. 2016

View full text Add to dashboard Cite

Hepatitis C genotype 3 (GT-3) infection comprises up to 30 % of all HCV infections worldwide, with roughly 54.3 million cases concentrated in South and Southeast Asia. Longitudinal studies have demonstrated significantly increased rates of steatosis, fibrosis, and hepatocellular carcinoma in GT-3 disease, thus distinguishing this genotype as both the most difficult and urgent to treat. However, novel direct-acting antiviral agents currently approved have not demonstrated the uniform potency seen in GT-1 disease for GT-3. This review outlines (1) the epidemiology and natural history, (2) phase II and III clinical trials demonstrating effective treatment options, and (3) current and future therapeutic issues in the quest to eradicate hepatitis C genotype 3 disease.

show abstract

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3

Cited by 26 publications

References 34 publications

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infection

‘Easy to treat’ genotypes were not created equal: Can rapid virological response (RVR) level the playing field?

Hepatitis C genotype 3 disease

Contact Info

Product

Resources

About